Potentiality of Exosomal Proteins as Novel Cancer Biomarkers for Liquid Biopsy

Chunmiao Hu1,2, Wei Jiang2, Mingjin Lv2, Shuhao Fan1, Yujia Lu1, Qingjun Wu2* and Jiang Pi1*

1 Institute of Laboratory Medicine, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China, 2 Department of Cellular Biology, Dakewe, Shenzhen, China

Liquid biopsy has been rapidly developed in recent years due to its advantages of non-invasiveness and real-time sampling in cancer prognosis and diagnosis. Exosomes are nanosized extracellular vesicles secreted by all types of cells and abundantly distributed in all types of body fluid, carrying diverse cargos including proteins, DNA, and RNA, which transmit regulatory signals to recipient cells. Among the cargos, exosomal proteins have always been used as immunoaffinity binding targets for exosome isolation. Increasing evidence about the function of tumor-derived exosomes and their proteins is found to be massively associated with tumor initiation, progression, and metastasis in recent years. Therefore, exosomal proteins and some nucleic acids, such as miRNA, can be used not only as targets for exosome isolation but also as potential diagnostic markers in cancer research, especially for liquid biopsy. This review will discuss the existing protein-based methods for exosome isolation and characterization that are more appropriate for clinical use based on current knowledge of the exosomal biogenesis and function. Additionally, the recent studies for the use of exosomal proteins as cancer biomarkers are also discussed and summarized, which might contribute to the development of exosomal proteins as novel diagnostic tools for liquid biopsy.

Keywords: exosomal proteins, biomarkers, cancer diagnosis, liquid biopsy, exosome

INTRODUCTION

Tissue biopsy is widely applied as the gold standard for clinical cancer diagnosis. Nonetheless, tissue sampling becomes a substantial challenge once the tumor is adjacent to major blood vessels, which would make the surgical sampling procedures extremely invasive and painful. In addition, there are also some circumstances in which the small dissected tissues of patients may not be sufficient to represent the pathological profile of the primary tumor (1). Due to the above limitations, liquid biopsy has emerged as the most capable substitute for tissue biopsy due to the advantage of the much more easily accessible samples, such as urine, blood, and cerebrospinal fluid. Multiple sources of tumor-derived substances including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes can be detected from these body fluid samples and can be quickly analyzed (2). Hence, reliable real-time information can be acquired that can help in making a cancer prognosis and monitoring the physiological state of patients with repeated non-invasive sampling (3).
Masked by billions of host cells and vast quantities of free DNA released from normal cells, CTCs and ctDNA are scarcely dispersed in blood. Therefore, it is essential to isolate and enrich CTCs and ctDNA with elaborate techniques that possess high selectivity and sensitivity to carry out clinical analysis (4, 5). However, the enrichment of CTCs remains a big challenge for the application of CTCs, which is restricted by limited cancer surface markers and hindered by a rather limited number of CTCs themselves in the body fluids of cancer patients (6). ctDNA is generally thought to be secreted by necrotic and apoptotic cells. Although its abundance is higher than that of CTCs (7), ctDNA fragments have a very short half-life, even less than 1 h, and are rapidly cleared off (8). Based on these difficulties, the development of exosomes for liquid biopsy has gained increasing attention.

One of the greatest strengths of exosome-based liquid biopsy over CTCs (0–1,000 cells per 7.5 ml of blood) (9) and ctDNA is the larger distributed quantities of exosomes in the body fluids (up to 10^{11} exosomes per ml in the blood) (10). It is not an exaggeration that up to 10% of the circulating exosomes in a cancer patient would be tumor-derived exosomes at the late tumor stage (10, 11). Circulating RNA including mRNA and miRNA is also suggested to be a significant functional mediator in some cancers (8), but the worse stability in the plasma and other intricate causes hinder the clinical use of cell-free RNA (12). On the contrary, another advantage of exosomes as a promising diagnostic marker is that the cargos inside exosomes are well-protected by their lipid bilayer, which makes the intact tumor-derived entities such as RNA, DNA, and proteins carrying the comprehensive oncogenic information to be obtained and identified right after exosome isolation (13). An example of that is the family of phosphorylated proteins, which are usually degraded by the free circulating phosphatase, making them very difficult to be detected in the body fluid. However, these phosphorylated proteins can be well isolated from exosomes and stored stably in the exosomal form for as long as 5 years at −80°C (14). The fact that different cargos are sorted into exosomes as a protective vesicle makes multicomponent analysis feasible, which is conducive to a full-scale knowledge of how exosomes function and what the consequence is. Therefore, the sum of tumor-derived exosomes can be representative of the tumor heterogeneity (15). Moreover, combined research data have shown and confirmed that tumor-derived exosomes and their encapsulated proteins play important roles in cancer progression, which indicates the enormous potentiality for tumor-derived exosomal proteins as novel cancer biomarkers in liquid biopsy (16).

Nucleic acids in exosomes have been intensively investigated as cancer biomarkers. Nonetheless, increasing evidence suggests that proteins of tumor-derived exosomes circulating in the body fluids can also be the precise representative of relevant tumors in distant tissues. Here in this review, the potential of exosomal proteins as liquid biopsy biomarkers in future clinical research has been discussed. The biogenesis and function of exosomes, along with the latest isolation and characterization methods, have been discussed. The application of different exosomal proteins as tumor liquid biopsy targets in different research studies and the future development of exosomal proteins as powerful diagnostic targets in hospitals have been elaborated on in this review.

## BIOLOGY AND FUNCTION OF EXOSOMES

### Biogenesis and Composition of Exosomes

Extracellular vesicles (EVs) are particles naturally secreted by cells. They are delimited by a lipid bilayer but do not have a functional nucleus for self-replication (17). According to the process of formation, EVs are classified into two categories: exosomes and ectosomes. Ectosomes are formed by direct exocytosis of the plasma membrane (PM) (18). By contrast, exosomes are the product of consecutive internalizations of PM and are finally released by fusion with PM. Consecutive PM internalizations include the first inward budding of PM to form early endosomes, which will then mature into late endosomes. Second, invagination of the membrane in late endosomes gives rise to several intraluminal vesicles (ILVs) containing various constituents such as DNA, RNA, enzymes, and proteins. These late endosome-containing ILVs are also recognized as multi-vesicular body (MVB). Finally, MVB will fuse with PM, and ILVs will be released as exosomes into the extracellular milieu with PM-derived membrane (19, 20) (Figure 1). The generation of exosomes can be both ESCRT (endosomal sorting complexes required for transport)-dependent and ESCRT-independent (21).

Exosomes can be secreted by all types of cells including eukaryotic and prokaryotic cells (14, 20). Negatively stained exosomes display classic cup-shape and lipid bilayer structure under electron microscopy (EM), with a generic size range of 40–160 nm (~100 nm on average) in diameter and a density range of 1.15–1.19 g/ml (22). Diverse contents including nucleic acid, protein, lipid, and metabolite can be sorted and packaged into exosomes, which reflect the biological properties of parental cells in different scenarios.

Similary to cell purification and isolation, proteins are widely used as surface and internal markers for the isolation, characterization, and investigation of exosomes. According to the statistical study of data from ExoCarta, a database of exosome cargos, there are approximately 10,000 different exosomal proteins that have been characterized, and the number is believed to be growing over time (23). The proteins wrapped up in exosomes can be divided into three major groups according to their functions: biogenesis relevant (tetraspanins and ESCRT machinery), transport and secretion relevant (heat shock proteins and membrane transport proteins and cytoskeletal proteins), and cell of origin relevant (major histocompatibility complex (MHC) molecules and cytokines and other proteins) (10). CD9, CD63, CD81, and CD82 are the main tetraspanins that are associated with cargo selection machinery and biogenesis of exosomes, and CD63 is the protein marker mostly utilized for immunocapture of exosomes. Representative ESCRT machinery proteins are TSG101 and Alix. Heat shock protein, Rab GTPase, annexin, flotillin, syntaxin, actin, and tubulin are the common
Exosome transport-related proteins. However, the role of heat shock proteins in the biogenesis of exosomes needs further investigation (24). Some specific exosomes also contain MHC molecules of antigen-presenting cells (APCs) and cytokines like interleukins that are accommodated with immune responses (19).

Exosomal nucleic acids are comprised of DNA, mRNA, miRNA, and lncRNA. As research moves further, the level of miRNA in exosomes was found to be more condensed over other species of nucleic acids from parental cells (25). Compared to other nucleic acids, miRNA is the most widely studied component in exosomes and is found to play a significant role in exosome-mediated cell–cell communication (26, 26, 31, 32), which therefore attracted increasing attention from the scientific field to explore the potential of exosomes as the diagnostic analyte and drug delivery carrier ever since.

Function of Exosomes
The biogenesis and content of exosomes have determined their destiny and mission as intercellular messengers. When parental cells produce and secrete exosomes, those exosomes carrying proteins, lipids, metabolites, and nucleotides can transfer via the extracellular matrix (ECM) and circulation system and to any site of our body. Recipient cells with different varieties can internalize those exosomes by different patterns, such as clathrin-dependent endocytosis (33) or direct fusion with PM (34). Once uptaken, exosomes will deliver their cargos into cells for the regulation of multiple cellular activities, such as cellular development, immune response, and disease condition of recipient cells (19). For example, exosomal DNA can promote the cGAS-STING signaling pathway and pro-inflammatory response (35). Additionally, exosomal miRNA can also show regulatory functions during pregnancy (36). APCs like macrophages or dendritic cells can produce exosomes that carry MHC molecules with antigen peptides. Afterward, T cells are primed and activated when they uptake those exosomes via T-cell receptor (TCR)–MHC–peptide recognition (37).

FIGURE 1 | Biogenesis and composition of exosomes. First invagination of plasma membrane (PM) forms the early endosomes that contain multiple constituents, which will then mature into late endosomes. Second, invagination of membrane of late endosomes generates multi-vesicular body (MVB) containing intraluminal vesicles (ILVs). ILVs are secreted into extracellular milieu as exosomes with cargos including DNA, RNA, and proteins.
tumor-derived exosomes can assist tumor cells to escape from the surveillance of the immune system and develop the capability of chemoresistance, which further promote tumor progression. Some studies have revealed that tumor-derived exosomes can inhibit the cytotoxicity of natural killer cells and cytotoxic T lymphocytes, both of which are indispensable players of the immune mechanism against tumor progression (44, 45). Macrophages and dendritic cells are the pivotal mediators of innate and adaptive immunity, and they are not spared. Tumor-derived exosomes have shown to induce the polarization of immature macrophages into M2 macrophages and display anti-inflammatory activities favoring the ongoing tumor progression (46). Evidence has also shown that maturation of dendritic cells can be suppressed by tumor-derived exosomes, which affects the antigen priming and the activation of antitumor lymphocytes, both of which are indispensable players of the immune mechanism against tumor progression (44, 45). Moreover, when it comes to viscous samples like a serum, filtration is used for ultrafiltration, which can bind to a type I transmembrane protein called Tim-4. The binding specificity was developed as a novel method by Nakai et al. to separate phosphatidylserine-rich exosomes (53). Compared to PEG co-precipitation, separation by this method results in fewer contaminants. However, the yield of exosomes might also include other components such as microvesicles that also contain phosphatidylserine. Interestingly, there are two commercial kits that are likely associated with affinity membrane, including exoEasy from QIAGEN and Capturem from TaKaRa.

**ISOLATION AND CHARACTERIZATION METHODS**

The characteristics of exosomes are exploited as powerful targets in liquid biopsy and therapy. Nevertheless, the biggest challenge faced for their further application in clinical research and liquid biopsy is the difficulty in obtaining a purified population of exosomes from different sources of samples and accurately characterizing them as authentic exosomes. Although traditional methods like ultracentrifugation remain the gold standard, their unsuitability becomes increasingly obvious due to the requirement of expensive equipment, prolonged working hours, and a large amount of labor (49, 50). On the contrary, new methods like microfluidics take advantage of different traits of exosomes and create opportunities for the transition of exosome research from bench to bedside. The isolation method based on size exclusion or hydrophobic interaction-related mechanism can separate total exosomes from fluid samples. However, the results and yield of purified exosomes among different isolation methods are distinct from one another (51). In addition, there are specific methods that can select subpopulations of exosomes by surface protein markers. In this section, methods based on exosomal proteins will be briefly discussed in terms of suitability for clinical application.

**Isolation Methods**

**Polymer Co-Precipitation**

Polyethylene glycol (PEG) is cheap and easy to obtain, and the whole purification process does not require complex equipment, except for low-speed centrifugation. Therefore, many commercial kits have emerged based on the above strengths of PEG co-precipitation, like ExoQuick, Exo-spin, and Total Exosome Isolation. Commercial kits not only save time but also provide relatively standard experimental procedures to eliminate human errors, which therefore are very favorable to clinical labs. Samples of purified exosomes are often contaminated by junk components during isolation (52). When dealing with a serum that contains plenty of lipid proteins and albumin, it is recommended to remove such interference before the use of kits if high purity is required.

**Affinity-Based Isolation**

The membrane of exosomes is enriched with phosphatidylserines, which can bind to a type I transmembrane protein called Tim-4. The binding specificity was developed as a novel method by Nakai et al. to separate phosphatidylserine-rich exosomes (53). Compared to PEG co-precipitation, separation by this method results in fewer contaminants. However, the yield of exosomes might also include other components such as microvesicles that also contain phosphatidylserine. Interestingly, there are two commercial kits that are likely associated with affinity membrane, including exoEasy from QIAGEN and Capturem from TaKaRa.

**Ultrafiltration**

Based on the size and molecular weight, ultrafiltration is used for exosomes enrichment. However, before loading the sample onto an ultrafiltration column, it is usually recommended to perform sequential centrifugation steps to totally remove cells and debris, followed by a one-time filtration step through a 0.45-μm filter to remove large apoptotic bodies (54). Likewise, ultrafiltration is easy to conduct, and it saves both time and labor. But exosomes can remain retained in the filtration membrane during centrifugation, which not only hinders effective separation but also leads to a big loss of yield with insufficient elution (55). Moreover, when it comes to viscous samples like a serum, ultrafiltration shows lesser efficiency. Therefore, the method should be chosen according to the sample of interest to ensure a better separation of exosomes.

**Size Exclusion Chromatography**

Size exclusion chromatography (SEC) is another popular exosome purification method based on the size property of exosomes. It can separate exosomes efficiently from impurities (proteins, lipids, etc.) with well-maintained biological activity. Nonetheless, traditional SEC requires a very long time to run with the existence of contamination in the products (56, 57). But there is a commercial automated instrument from iZON that can be taken into consideration for clinical uses, which is claimed to optimize the running time from hours to minutes.

**Immunoffinity Capture**

Methods of immunoffinity isolation usually contain two components, streptavidin-coated magnetic beads and biotinylated purified monoclonal antibodies, which can be combined via a streptavidin–biotin bond. Antibodies with high affinity will catch corresponding target exosomal proteins to make sure that the exosomes are captured and gathered by a
magnet (58). Tetraspanins including CD9, CD63, and CD81 are generally used as targets because these proteins are recognized as ubiquitous markers expressed among exosomes regardless of origin (19). Methods of immunoaffinity do not involve complicated procedures, while the field of monoclonal antibody production is mature enough to guarantee the quality of antibodies. Therefore, the immunoaffinity capture method is appropriate for clinical applications. However, it is worth to be considered that exosomes isolated by the immunoaffinity method cannot get rid of magnetic bead-bound antibodies, which may influence the bioactivity of exosomes and the experimental results of downstream assays. Surprisingly, a new branch of aptamer-based technique emerged recently to show strong potential to resolve the disadvantage of antibody-based technique. The main advantage of the development of aptamers by exosome researchers is that aptamers are easier to synthesize and produce than antibodies (3). Notably, a group successfully separated exosomes with CD63 aptamer and then discharged bound exosomes by adding complementary nucleotide strands to separate exosomes from aptamer. This method could largely maintain the integrity and activity of exosomes, which further reinforces the power of the aptamer-based isolation technique for exosome research (59). Figure 2 provides an illustrative procedure of representative methods, and Table 1 provides the comparisons among the mentioned isolation methods with their characteristics.

To achieve a higher yield and purity of exosomes from clinical samples like body fluids, it is recommended to combine different isolation methods along with the pretreatment of clinical samples as mentioned above. In a methodology study of exosome isolation, Lobb et al. showed that ultrafiltration competed over ultracentrifugation, and coupling ultrafiltration with SEC resulted in a high yield of exosomes with high purity (60). They pointed out that the yield of exosomes differed among the application of different isolation methods, which suggested that the size and species of samples need to be taken into account before choosing a compatible isolation method. Another study used ultrafiltration in a company with size exclusion liquid chromatography, which proved that the combination of different methods could also preserve the bioactivity of purified exosomes (61). Scientific and clinical research on exosomes has attracted much attention so far, which impelled the development and revolution of the exosome isolation methodology. Nonetheless, existing methods are still mostly working with tissue cultures, and the results sometimes are not compatible with physical conditions (62). Additionally, the experimental results obtained on similar samples are controversial due to the different amounts of samples and different protocols that are used by different groups (63). Therefore, it is urgent to develop standardized methods to better assist the research of exosomes as well as to facilitate the translation of exosome-based techniques for clinical application in liquid biopsy.

**Characterization Method**

**Microscopy and Nanoparticle Tracking**

It is recommended and encouraged to characterize exosomes by two indispensable and complementary techniques, which usually are EM and nanoparticle tracking analysis (NTA) (19). The former provides the image of exosome morphology, and the latter gives information on the size distribution and...
concentration of exosomes (17). It is necessary to obtain a clear and high-resolution image of exosomes to ensure that the intact structure of exosomes is maintained, which requires hours of microscopy operation and observation (64). Cellular experiments like the uptake of exosomes in the absence of cell-cell contact are sometimes used to demonstrate the bioactivity of purified exosomes. NTA detects the Brownian movement of total nanoparticles of a sample but is unable to distinguish the phenotype or the origin of exosomes (65).

Bicinchoninic Acid Assay, Western Blotting, and ELISA

Bicinchoninic acid assay (BCA) is one of the most widely used methods for exosome protein quantification. By combining the examined amount of protein with the concentration of exosome particles, general knowledge of the quantity and purity of the exosome sample can be obtained. Nevertheless, the contaminant proteins can influence the authentic result. Western blotting and ELISA are the most used methods for the characterization of the exosomal composition, and the presence of certain proteins can be confirmed; however, the results are also affected by contaminant proteins, as they cannot separate exosomal proteins from non-exosomal proteins (66). It is suggested by MISEV that at least three positive and one negative protein marker of exosomes should be conducted in Western blotting for exosome characterization (17). For samples like serum or plasma, the most recommended negative markers for exosome characterization are apolipoproteins A1/2 and B as well as albumin (17, 67). However, there are also some contradictory studies indicating the presence of apolipoproteins A and albumin in exosomes (68, 69). Therefore, cytochrome C, a protein of mitochondria, and other endoplasmic reticulum (ER) and Golgi proteins such as calnexin, BIP, GRP94, and GM130 are suggested as negative markers for exosomes instead (17). It is sometimes necessary to remove disturbing proteins to get a cleaner background and a better readout.

Flow Cytometric Analysis

Regular flow cytometric devices detect and analyze targets at the cellular level, and thus it is a great challenge to apply them at the nanosized level. To be analyzed by a flow cytometric machine, exosomes should be immobilized on microbeads first and then bound with fluorescent antibodies, which make the fluorescence detectable as a positive signal. The good news is that the recent development of flow cytometric instruments reduces the detection limit to 100 nm (9), which strongly favors future exosome analysis in clinical situations. A major strength of flow cytometry is that it can recognize and select specific subpopulations of exosomes by specific protein markers. Meanwhile, the number of those fluorescence-bearing exosomes can be calculated (70).

Microfluidics

As increasing evidence has revealed the significant role of exosomes in cancer progression, some research groups have coined microfluidics for clinical isolation and analysis of exosomes. Usually, microfluidics is a combined system of isolation, characterization, and analysis modules, enabling a complete flow of diagnosis based on exosomes. Microfluidics has the same principles as conventional isolation methods such as immunoaffinity capture and fluorescent analysis. But compared to conventional methods, microfluidics requires much less time and amount of sample, which makes it more clinically favorable. One of the representative examples of microfluidics is developed by the combination with flow cytometry, whose sensitivity reaches 10,000 exosomes per ml of serum (9). We can recognize the microfluidics platform as a scaled-down version of common methods, but with higher sensitivity and throughput, which therefore maintains the great potential for liquid biopsy (72). Nonetheless, the method of microfluidics should be further standardized before being widely applied. A brief comparison of different methods of exosome characterization is summarized in Table 2.

APPLICATION OF EXOSOMAL PROTEINS IN LIQUID BIOPSY

The field of exosome research has put a huge effort into exploring exosomal miRNA as an attractive biomarker for cancer diagnosis because of the discovered correlation between the increased level of miRNA and the manifestation of cancer. However, it has been

TABLE 1 | Comparison of different exosome isolation techniques.

| Isolation technique | Underlying mechanism | Working scalability | Sample purity | Advantage | Disadvantage | Reference |
|---------------------|----------------------|---------------------|---------------|-----------|--------------|-----------|
| Polymer co-precipitation | Hydrophobicity of protein and lipid | Small | Low | Cheap, fast, easy | Contaminated by co-precipitated particles | (52) |
| Affinity-based isolation | Affinity | Small | High | Fast, easy | Expensive, contaminated by microvesicles | (53) |
| Ultrafiltration | Molecular weight | Medium | Medium to high | Fast, easy | Plugged up easily by vesicles | (54, 55) |
| Size exclusion chromatography | Size and molecular weight | Flexible | High | Cheap, easy, reproducible | Time-consuming | (56, 57) |
| Immunoaffinity capture | Immunoaffinity-antibody | Small | High | Fast, easy | Expensive, contaminated by magnetic beads | (58) |
| Ultracentrifugation | Immunoaffinity-aptamer | Small | High | Cheap, fast, easy | Low recovery | (3, 59) |
| | Differential density | Small | Flexible | Well-established and commonly used | Time-consuming, ultraspeed centrifuge required | (49, 50) |
neglected that exosomal proteins can also serve as diagnostic biomarkers of cancer due to the following advantages: 1) protein constituents from tumor-derived exosomes reflect the proteomic profile of their parent tumor cells. Thus, circulating exosomes in the body fluids can provide comprehensive information about the distal primary tumor by the exosomal proteins (62). 2) Tumor-secreted proteins are greatly diluted by background substances in the circulating blood, making them very difficult to be detected. Enrichment of exosomes from blood can make it much easier to detect the proteins wrapped up in exosomes (13). 3) Many proteins secreted by tumor cells are unstable and vulnerable due to the presence of free protease in the body fluids. But these proteins can be well protected within tumor-derived exosomes, enabling in-depth analyses of relevant tumors (14). 4) Different miRNAs can lead to a similar consequence of derived exosomes, enabling in-depth analyses of relevant tumors (26), while the phenotypes of proteomic profiles can be more straightforward and representative of parent cells. Nevertheless, with increasing research on exosomal proteins for biomarker application, new challenges arise. For instance, the inconsistency among different cohorts of study is found even in the analysis of the same exosomal protein. Although there is still a long way to go, the development and application of exosomal protein as a powerful diagnostic tool for cancer therapy possess a bright future with tremendous potential. In this section, exosomal proteins that have been identified as tumor-associated markers by clinical research will be summarized and discussed. In vitro studies with cell culture or mouse models will not be covered because more attention has been paid to clinical studies, which present more relevant results to authentic physical situations. Exosomal proteins discussed here are summarized in Tables 3–6.

**Tetraspanin and Surface Protein**

Tetraspanins such as CD9, CD63, and CD81 are considered the major components of exosomal transmembrane proteins, which participate in the biogenesis and cargo sorting of exosomes (108). These three tetraspanins are also used most frequently as targets conjugated with the immunoaffinity capture method. Nevertheless, it has been noted that CD63 was less presented in all of the tested samples (109–111), which queries the widely accepted concept that CD63 is ubiquitously existed on the surface of exosomes and urges us to explore new exosomal signature proteins. Tumor-derived exosomes are known to play important roles in the process of tumor generation, progression, and EMT, as exosomal tetraspanins can interact with receptors like integrins on recipient cells for the enhanced uptake of tumor-derived exosomes. Hence, exosomes with increased expression of tetraspanins have been widely identified in the body fluids of cancer patients by different research groups. The correlation of tetraspanins with tumors also makes these exosomal surface proteins strong biomarkers for various cancers (112). An earlier proteomics study suggested that the expression of exosomal CD9 significantly varied among cancer tissues and relevant normal tissues (113). Recently, these proteins, including CD9, have been increasingly demonstrated to be closely relevant to cancer-derived exosomes by different groups, thus possessing tremendous potential as cancer biomarkers. An assay called ExoScreen was developed by the group of Yoshioka et al. (76) to screen exosomes with surface expressions of CD63 and CD9 from only 5 μl of serum from colorectal cancer patients without any sample preparation procedures such as dilution or purification. This assay combined two groups of antibodies conjugated with a donor photosensitizer bead and an acceptor photosensitizer bead. It was also found that the level of CD9 and another surface molecule CD147 was significantly increased in the serum of colorectal cancer patients (114). Notably, the higher level of CD147/CD9 in serum exosomes could also be detected at an early stage of cancer, with the area under the curve (AUC) of 0.820 among healthy donors versus patients. The regular reference tumor-associated antigens carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were within the normal value range (termed non-cancer) with the AUC of 0.669 and 0.622, respectively, indicating the great potential of exosomal proteins as cancer biomarkers with higher specificity and sensitivity than a regular signature. In another smaller cohort of studies about prostate cancer, Krishn et al. also confirmed that the CD9 level increased in plasma exosomes from patients

### TABLE 2 | Comparison of different exosome characterization techniques.

| Characterization method          | Exosome property                              | Advantage                                               | Disadvantage                                                     | Reference       |
|---------------------------------|-----------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------|-----------------|
| Physical characterization       |                                               |                                                         |                                                                 |                 |
| Electronic microscopy           | Morphology, size distribution                 | Necessary process for nanosized exosome morphological feature characterization | Time-consuming, affected by human factors like visual sense | (64)            |
| Nanoparticle tracking analysis  | Size distribution, concentration in solution  | Fast and easy, in combination with microscopy for exosome physical property characterization | Unable to determine the phenotype of exosomes | (17)            |
| Biochemistry characterization   |                                               |                                                         | Low sensitivity, long preparation procedure, unable to exclude contaminants from exosomes | (66)            |
| Western blotting                | Presence and level of protein                 | Classic and standardized method for protein analysis    | Expensive, unable to exclude contaminants from exosomes         | (66)            |
| ELISA                           | Presence and level of protein                 | Classic and standardized method for protein analysis    | Resolution limit restricts the sensitivity, low amount of protein reduces the fluorescence signal for detection | (70)            |
| Flow cytometry                  | Protein specificity and concentration in solution | Able to identify subpopulation of exosomes with specific protein markers |                                                                 |                 |
compared to that of the healthy control group. Along with the upregulated CD9 levels on exosomes, the authors also found that αvβ3 integrin was also expressed in plasma exosomes of cancer patients, but the expression of another classic tetraspanin CD81 decreased somehow in cancer patients. However, a similar change was not found in the RNA level of CD9 and CD81 between healthy and disease conditions, suggesting that there should be an intriguingly complicated regulatory network involved in the process. Additionally, exosomal proteins should be more straightforward and convincing than exosomal RNA to reflect the cellular activity in a sense (78). Moreover, a higher expression of exosomal CD9 in plasma from prostate cancer patients had also been revealed in another study by differential centrifugation. However, these results came from a small-scale study with only six recruited patients and thus should be verified by identical experiments with a larger cohort. Nevertheless, they investigated the role of CD9 in prostate cancer and found that exosomal CD9 could promote cancer cell proliferation (79). An additional study on bladder cancer also reported an elevated level of CD9-positive exosomes in urinary samples (105). It looks like CD9 can promote tumor growth in different types of cancers, but an in vivo experiment has shown a contradictory result that the knockout of CD9 in hepatocellular carcinoma can facilitate cancer development instead. Additionally, it was also reported that there was no difference between the number of exosomes released by hepatocellular carcinoma cells before and after the overexpression of CD9 and CD81 (115). Although the results obtained from cell lines do not always display exactly the same in clinical scenarios, the complicated roles of CD9 discussed here should remind researchers that solid conclusions require more reliable comparative discoveries, especially regarding exosomes that are naturally heterogeneous.

Meanwhile, an in-house study of melanoma reported that there was a higher level of CD63+ exosomes in cancer plasma, which was correlative with the level of caveolin-1, a component of caveolae (81). Another pilot study with oral squamous cell carcinoma patients showed that the level of CD63+ exosomes decreased immediately after resection surgery, suggesting that the tumor was responsible for the high level of CD63+ exosomes in the circulation (82). In addition, to be potential candidates for cancer biomarkers, a recent study using immunohistochemistry (IHC) showed that tumor exosomal CD9 and CD63 might also act as potential prognostic monitors due to the increased expression in rectal tumor tissue after chemoradiation treatment (116). Although it is helpful to build our understanding of pathology by tissue biopsy, the result should be further verified with body fluid samples since liquid biopsy application of exosomes holds great promise in non-invasive personal precision medicine. So far, very few studies have investigated three tetraspanins (CD63, CD9, and CD81) together in clinical settings; therefore, it is still unclear whether the level of CD9, CD63, or CD81 correlates with different types of cancers.

### Table 3: Exosomal tetraspanin and surface markers.

| Type of cancer | Protein marker | Number of patients/controls | Source of exosome/amount of Sample | Isolation technique | Diagnostic accuracy of proposed marker | Reference |
|----------------|----------------|----------------------------|-----------------------------------|---------------------|---------------------------------------|-----------|
| Lung cancer    | CD9            | 105/73                     | Serum/50 µl                       | MSIA                 | AUC = 0.724, sensitivity = 60.0%, specificity = 89.0%. | (73)      |
|                | TSPAN8, CD151  | 336/126                    | Plasma/10 µl                     | EV array             | AUC_{TSPAN8} = 0.60, AUC_{CD151} = 0.68. Patient group is composed of individuals with three types of lung cancer. Control group is composed of non-cancer patients having symptoms of cancer. | (74)      |
| Breast cancer  | CD9, CD147     | 80/80                      | Serum/500 µl                     | ExoQuick Kit (SBI)   | Significantly increased in 30 representative samples. Control group is composed of patients with benign breast disease. AUC_{CD9,CD147} = 0.820. Double-positive exosomes were used as diagnostic markers. | (75)      |
| Colorectal cancer | CD9, CD147     | 194/191                    | Serum/5 µl                       | ExoScreen            | Positive in 90% of patient samples. Control group include patients with chronic pancreatitis benign pancreatic tumor and non-pancreatic tumor and healthy volunteers. | (76)      |
| Pancreatic cancer | TSPAN8         | 131/79                     | Serum/1–1.5 ml                  | Sucrose gradient ultracentrifugation | Positively increased among nine representative patient samples. | (77)      |
| Prostate cancer | CD9, CD81      | 70/14                      | Plasma/over 3 ml                | Ultracentrifugation  | Positively increased (CD9) in five representative patient samples. | (78)      |
|                | CD9            | 6/10                       | Plasma/2,500 µg of protein       | Ultracentrifugation/UV assay | Significantly decreased (CD81) in four representative patient samples. | (79)      |
|                | P-glycoprotein | 4/6                        | Serum/1 ml                      | Differential centrifugation | Significantly increased in six representative samples. | (80)      |
| Melanoma       | CD63           | 90/58                      | Plasma/ unspecified             | Ultracentrifugation  | Increased in 4 docetaxel-resistant prostate cancer compared to 6 treatment-naïve patients. Sensitivity = 96.5%, specificity = 43%. AUC unspecified. | (81)      |
| Oral squamous cell carcinoma | CD63 | 10                          | Plasma/1 ml                     | Ultracentrifugation  | Significantly decreased among 10 representative samples. Comparison was made between patients before and after surgery. | (82)      |

EV, extracellular vesicle; AUC, area under the curve.
TABLE 4 | Exosomal transport protein, heat shock protein, and adhesion protein.

| Type of cancer | Protein marker | Number of patients/controls | Source of exosome/amount of sample | Isolation technique | Diagnostic accuracy of proposed marker | Reference |
|----------------|----------------|-----------------------------|-----------------------------------|-------------------|---------------------------------------|-----------|
| Lung cancer    | HSP70          | 18/19                       | Plasma/10 ml blood                | Ultracentrifugation | AUC = 0.8968 for distinguishing metastatic stage of cancer (including lung cancer and breast cancer). Comparison was made between patients with metastatic cancer and non-metastatic cancer. AUC = 0.844. | (83)      |
|                | Fibronectin    | 21/41                       | Serum/unspecified                 | Sucrose gradient ultracentrifugation | Significantly increased in six patients with late-stage gastric cancer. | (85)      |
| Gastric cancer | PSMA3/PSMA6    | 24/13                       | Serum2/ ml                        | exoEasy Maxi Kit (QIAGEN) | Significantly decreased in 18 representative samples. | (86)      |
| Colorectal cancer | HSP90       | 18/18                       | Serum/250 µl                      | Total Exosome Isolation Kit (Invitrogen) | | |
| Prostate cancer | αvβ3           | 70/14                       | Plasma/over 3 ml                  | Ultracentrifugation | Significantly increased in representative samples. | (78)      |
|                | ACTN4          | 20/8                        | Serum/unspecified                 | Sucrose gradient ultracentrifugation | Significantly increased in castration-resistant prostate cancer compared to prostate cancer patients receiving primary androgen deprivation therapy. | (87)      |
| Pancreatic cancer | ZIP4       | 24/78                       | Serum/500 µl                      | ExoQuick Kit (SBI) | AUC = 0.89 for distinguishing malignant cancer from benign pancreatic disease. AUC = 0.8931 for distinguishing malignant cancer group from normal group. [Number of controls include benign pancreatic disease (32) and normal subjects (46)] | (88)      |
| Endometrial cancer | ANXA2      | 41/20                       | Plasma/500 µl                     | ExoGAG             | AUC = 0.748. | (89)      |
| Gynecologic cancer | HSP22       | 30                          | Serum/1 ml                        | Ultracentrifugation | Comparison was made among patients with ovarian cancer, patients with endometrial cancer and patients with endometriosis. Although no significant result was concluded. | (90)      |

If no specified AUC, sensitivity, or specificity is claimed in the reference, no precise numerical data for diagnostic accuracy are included in this table.

AUC, area under the curve.

Some other surface molecules expressed on exosomes were also reported as strong cancer biomarkers. In a large cohort study of lung cancer patients, an EV array was built that contained 49 exosomal and tumor proteins to collect the heterogeneous populations of exosomes from 472 isolated plasma samples. The expressions of two tetraspanins CD151 and TSPAN8 were found to be significantly elevated in exosomes from cancer patients, which could distinguish cancer from healthy control with AUC of 0.68 and 0.60, respectively, independently of disease stage and histological subtype. Following that, the combination of 8 proteins along with CD151 and TSPAN8 was determined to have the best separation outcome to distinguish cancer sample from healthy control with the largest AUC of 0.74, which suggested that a group of protein markers may have higher sensitivity than an individual marker in diagnosis (74). Another proteomic analysis presented similar data to show that the expression of exosomal TSPAN8 was associated with pancreatic cancer as well (77). A study on breast cancer demonstrated that the level of CD82 in serum-derived exosomes was significantly higher in a malignant group than in the healthy control group. The results also suggested that the level of CD82 was positively correlated with the malignancy of breast cancer and thus could sensitively serve as a breast cancer marker (75). There were also some other reports showing the increased level of exosomal CD91 and P-glycoprotein in the clinical case of lung cancer and prostate cancer, respectively (73, 80), indicating their potential for cancer analysis. Interestingly, the AUC of CD91 combined with CEA in distinguishing lung cancer reached 0.882 (73, 80), which substantiated CD91 as a very good candidate for potential lung cancer diagnosis.

There is a great chance that the surface molecules discussed above will be applied widely in future clinical research on cancer diagnosis and liquid biopsy, while most of these encouraging findings were involved with two correlated proteins, like CD9 and CD147 or CD63 and caveolin-1, because it may not be enough to get a whole picture of a tumor merely by a single protein marker. By combining various biomarkers in one panel, the signature of cancer can be identified and analyzed more reliably, accurately, and efficiently. Though promising, the results shown here came from different groups by using different purification processes without any normalization. Future studies with standardized methods are necessary to exclude the contingencies of experiments that might induce the methods of exosome enrichment.

Transport Protein, Heat Shock Protein, and Adhesion Protein

TSG101, Alix, and heat shock proteins take part in the intracellular transport of exosomes, which therefore shows important implications in cancer (117–119). Elmira et al. reported in a recent study with over 400 samples that the level of exosomal TSG101 was significantly upregulated in colorectal tumor tissue (120). ANXA2, a member of the annexin family involved in the endocytosis and exocytosis processes, was identified to have an increasing level in plasma exosomes of endometrial cancer (EC) patients. The AUC of
TABLE 5 | Tumor-associated exosomal protein.

| Type of cancer          | Protein marker | Number of patients/ control | Source of exosome/ amount of sample | Isolation technique                      | Diagnostic accuracy of proposed marker                                      | Reference |
|-------------------------|----------------|-----------------------------|-----------------------------------|-----------------------------------------|---------------------------------------------------------------------------------|-----------|
| Glioblastoma            | EGFR           | 24/8                        | Plasma/ 100 µl                    | Differential centrifugation             | AUC<sub>EGFR</sub> = 0.78, sensitivity = 64.0%, specificity = 88.0%.             | (91)      |
| Lung cancer             | EGFR           | 9                           | Plasma/ 100 µl                    | Immunoadfinity capture                  | Positive in five representative samples.                                        | (92)      |
| Hepatocellular carcinoma | LG3BP, PIGR   | 29/32                       | Serum/1 ml                        | Ultracentrifugation                     | AUC<sub>LG3BP</sub> = 0.904. Sensitivity = 96.6%, specificity = 71.8%.           | (93)      |
| Colorectal cancer       | Glypican-1     | 102/80                      | Plasma/ 10 ml blood               | ExoCap<sup>TM</sup> kit (JSR)/ immunoaffinity capture | Significantly decreased in cancer patients after surgery treatment compared to patients before surgery treatment. Significantly increased in patients compared to healthy control. | (94)      |
| Pancreatic cancer       | c-Met          | 30/40                       | Serum/250 µl                      | Sensitivity = 70%, specificity = 85%.   | Diagnostic odds ratio = 13:2.                                                   | (96)      |
| Glypican-1              | 62/20          | Serum/250 µl                | Sucrose gradient ultracentrifugation | AUC = 1.0. Sensitivity = 100.0%, specificity = 100.0%.                          | (97)      |
| Glypican-1              | 27/16          | Plasma/ 1–1.5 ml            | Ultracentrifugation               | AUC = 0.59. Sensitivity = 74.0%, specificity = 44.0%.                           | (98)      |
| Glypican-1              | 24/26          | Serum/2 ml                  | Sucrose gradient ultracentrifugation | Control group is composed of patients with benign pancreatic disease.          | (99)      |
| Pancreatic ductal adenocarcinoma | Glypican-1 | 22/28                      | Serum/250 µl                      | Total Exosome Isolation Kit (Invitrogen) | AUC = 0.78 for GPC1+ exosomes in portal and peripheral blood.                  | (100)     |
| Ovarian cancer          | CD24, EpCAM, CA-125 | 15/5                        | Plasma/20 µl                      | ExoSearch Chip/ immunoadfinity capture | AUC<sub>CD24</sub> = 0.9067. AUC<sub>EpCAM</sub> = 1.000. AUC<sub>CA-125</sub> = 1.000 | (101)     |
| Melanoma                | PD-L1          | 44/11                       | Plasma/ 250 µl                    | TEI kit (Invitrogen)/ immunoadfinity capture | AUC = 0.9184. Sensitivity = 80.00%, specificity = 89.47%.                      | (102)     |
| Caveolin-1              | PD-L1          | 90/58                       | Plasma/ unspecified              | Size exclusion chromatography/ immunoadfinity capture | Sensitivity = 69%, specificity = 96.3%.                                         | (81)      |
| Head and neck squamous cell carcinomas | PD-L1 | 40                         | Plasma/1 ml                       | Size exclusion chromatography/ immunoadfinity capture | Significantly increased in cancer patients with active disease and late stage (UICC stage III/IV) cancer. | (103)     |

If no specified AUC, sensitivity, or specificity is claimed in the reference, no precise numerical data for diagnostic accuracy are included in this table.

AUC, area under the curve.

ANX2 as a biomarker for EC is 0.74, which therefore can serve as a relatively good marker suggested by the authors (89). HSP70 is actively released as exosome surface protein under the stimulation of high levels of IL-10 and IFN-γ in the serum of cancer patients, suggesting the role of exosomal HSP70 in tumor immunity and the potential of HSP70 as a cancer biomarker (121). Moreover, it was found that the number of HSP70<sup>+</sup> exosomes in the plasma samples from metastatic lung and breast cancer patients was significantly higher than that of healthy volunteers, in which the level of HSP70<sup>+</sup> exosomes was barely detectable (83). The same group further compared the performance of exosomal HSP70 vs. CTCs in their pilot attempt under clinical conditions and found that exosomal HSP70 could act as a discriminative marker between patients with non-metastatic lung cancer and metastatic lung cancer, possessing better AUC of 0.8968 than that of CTC detection (AUC = 0.7857). Under stress, the induced form of HSP70 is expressed exclusively by cancer cells, which is called HSP72. One of the conclusive reviews of HSP70 discussed that tumor-derived HSP72-containing exosomes promoted the immunosuppressive function of tumor-associated suppressor cells, indicating the diagnostic value of HSP72 as the target of cancer (121, 122). Other than HSP70, an integrin-mediated pathway-related heat shock protein HSP90 was also reported to be strongly downregulated in the serum of colorectal cancer patients compared to the healthy control group (86). Moreover, one of small heat shock proteins (sHSP), named HSP22, was found at a high level in exosomes from gynecologic cancer patients, which was further suggested to be correlated with host cytotoxic immune response (90). Subunits PSMA3 and PSMA6, belonging to the 26S proteasome complex that is responsible for the functional
modification and the degradation of cellular proteins, were shown to be enriched in serum-derived exosomes of gastric cancer patients (85). In addition, exosomal zinc transporter ZIP4 and integrin αvβ3 were also reported to be significantly related to tumor growth of pancreatic and prostate cancers, respectively (78, 88). In the latter study, to determine the origin of exosomes, C4-2B-β3-GFP cells were injected into NOD mice to develop prostate cancer, and the authors successfully isolated plasma exosomes with GFP-tagged αvβ3 integrin in the circulation, indicating the direct relevance between tissue-derived exosomes and circulating exosomes (78). Moreover, exosomal fibronectin was also confirmed by proteomic analysis on non-small cell lung cancer-derived exosomes to display great diagnostic potential in the clinical cohort (84). The actin cross-linking protein actinin-4, which could facilitate cancer metastasis, was also identified as a signature protein of metastatic prostate cancer with a high expression level (87).

**Tumor-Specific Protein**

Tumor-associated proteins such as CA19-9, CEA, and prostate-specific antigen (PSA) have been used as indicators in cancer diagnosis for a long time. Among those significant biomarkers, PD-L1 has become the focus of immunotherapy development. PD-L1, existing on the surface of various cell types including epithelial cells and tumor cells, can bind with PD-1 on the surface of T cells to act as the key immune checkpoint mediator in healthy conditions; however, it can also suppress the immune response of cytotoxic T cells in cancer. Overexpression of PD-L1 has been reported to be indicative of the status of tumors by using methods like IHC (123). Compared to tissue biopsy, liquid biopsy offers a safer way of sampling, which can be conducted at any time to acquire accurate information about the ongoing illness in patients. Due to that, research starts to focus on the investigation of the value of exosomal PD-L1 in liquid biopsy. A mechanism study has demonstrated that metastatic melanoma cells managed to escape from immune supervision by producing exosomes that carry PD-L1 to facilitate tumor growth as well as suppress CD8+ T cells. Additionally, the authors also found that compared to that in healthy donors, the level of PD-L1 in plasma exosomes was significantly higher in melanoma patients (102). Similarly, in patients with head and neck cancer, the expression of PD-L1 on the membrane of plasma exosomes was discovered to be associated with the progression of the disease, whereas soluble PD-L1 was not correlated with any of the results found with exosomal surface PD-L1 (103). This odd observation may suggest that the exosomal surface proteins exhibit the same expression pattern as parental cells. Nevertheless, a study on pancreatic cancer revealed controversial results showing that the level of PD-L1 on circulating exosomes was not correlated with cancer. On the contrary, another molecule c-Met displayed a strong correlation with cancerous parameters (96). Thus, based on these favorable findings, more future work should be done to provide convincing proof that exosomal PD-L1 can be developed as an excellent cancer biomarker.

Glypican-1 (GPC-1), a surface-bound proteoglycan that regulates signaling pathways mediated by TGF-β, Wnt, and other growth factors, is overexpressed in a variety of cancer tissues to promote cancer progression, especially pancreatic cancer (124, 125). Melo et al. purified serum exosomes from patients with pancreatic ductal adenocarcinoma (PDAC) and found that all exosome samples of PDAC patients (n = 190) were marked with high expression of GPC-1, suggesting a strong correlation between cancer and serum-derived exosomes. More than that, the authors analyzed the primary tumor tissue of PDAC patients and found the mutant transcript of Kras, an oncogenic gene that is frequently seen in PDAC. They compared the intensity of high-density glycosylation of CD133 significantly correlated with survival days of pancreatic patients. Non-malignant ascites from alcoholic and hepatitis C-related cirrhotic patients were considered as control.

| Type of Cancer | Protein Marker | Number of patients/controls | Source of exosome/amount of sample | Isolation technique | Diagnostic accuracy of proposed marker | Reference |
|----------------|----------------|----------------------------|----------------------------------|--------------------|----------------------------------------|-----------|
| Prostate cancer | TMEM256        | 16/15                      | Urine/50–150 ml                  | Ultracentrifugation | AUC = 0.87. Sensitivity = 94.0%, specificity = 100.0%. | (104)     |
| Bladder cancer  | TACSTD2        | 28/12                      | Urine/12.5 ml                    | Ultracentrifugation | AUC = 0.741. Control group is composed of 12 hernia patients. A higher AUC = 0.80 of TACSTD2 was obtained in a larger cohort of 221 samples with ELISA. | (105)     |
| Pancreatic cancer | CD133         | 19                         | Ascites/ unspecified             | exoEasy Maxi Kit (QIAGEN) | The intensity of high-density glycosylation of CD133 significantly correlated with survival days of pancreatic patients. Non-malignant ascites from alcoholic and hepatitis C-related cirrhotic patients were considered as control. | (106)     |
| Endometriosis   | ANXA2          | 22/6                       | Peritoneal fluid/1 ml            | Exo-spin Kit (Cell Guidance) | Specifically existed in endometriosis patients regardless of disease stage. | (18)      |
| Renal disease   | Polycystin-1   | 8                          | Urine/50 ml                      | Ultracentrifugation | Significantly increased in urinary exosomes. Comparison was made between urinary samples and kidney tissue samples. | (107)     |

If no specified AUC, sensitivity, or specificity is claimed in the reference, no precise numerical data for diagnostic accuracy are included in this table. AUC, area under the curve.

TABLE 6 | Tumor-associated exosomal protein in urine and ascites.
patients, which was decreased accordingly after the resection surgery of PDAC patients (98). However, in many studies with PDAC, the investigation of exosomal GPC-1 was usually combined with other surface markers, which were claimed to possess higher sensitivity and specificity for cancer detection. Buscail et al. reported that the combination with CA19-9 and CD63+ GPC-1+ circulating exosomes could define PDAC much better with an accuracy reaching 84% (100). Xiao et al. also addressed that a sensitive and reproducible detection panel consisting of exosomal GPC-1 and CD82 and serum CA19-9 could efficiently distinguish PDAC patients from healthy people (99). Furthermore, a multiparametric exosome profiling was also developed and conducted by screening exosomes from patient plasma with a combination of ten surface markers including four biomarkers from a major group of cancers, three putative PDAC markers including GPC-1, and three pan-exosome markers (126). Exosomal GPC-1 has also been demonstrated to be increased in colorectal cancer (94). The percentage of GPC-1+ exosomes among total exosome numbers was significantly higher in patients with more severe disease conditions (95). This percentage was also significantly increased in relapsed patients, indicating GPC-1 as a biomarker for diagnosis and poor prognosis (95). Collectively, these research data obtained with clinical samples greatly support the value of exosomal GPC-1 as a potential diagnostic marker for cancer screening.

CD24 is a type of cell adhesion molecule participating in cell recognition, activation, signal transduction, proliferation, etc., which has been found to be abnormally expressed in various cancers. Notably, Zhao et al. developed a multiplexed detection chip combined with protein markers CA-125, EpCAM, and CD24, which indicated a three-fold increase of exosomal CD24 in the plasma of ovarian cancer patients. The AUC values of CA-125, EpCAM, and CD24 were 1.0, 1.0, and 0.91, respectively, all indicating the great value of diagnosis (101). But Soltész et al. found that in the same type of cancer, the expression of CD24 RNA was not detectable in all plasma or exosome samples of the patients, though there is a significant alteration in the tissue of the same ovarian cancer patients (127). Thus the bias existing between exosomal protein and RNA remains to be solved, and it also signifies the importance of exosomal protein in liquid biopsy.

Epidermal growth factor receptor (EGFR), another protein specifically overexpressed in tumors, is closely associated with cancer progression. Yamashita et al. showed that the expression of EGFR on plasma exosomes was significantly higher in lung cancer patients compared to healthy controls, whereas the level of soluble EGFR in plasma showed no significant difference between healthy and disease conditions (92). In another study, a microfluidic chip combined with a nuclear magnetic resonance detection system was developed by Shao et al. to analyze the expressions of EGFR and its variant EGFR vIII on plasma exosomes of glioblastoma patients (91). They identified that the levels of EGFR and EGFRvIII in exosomes were significantly higher in patients compared to healthy individuals.

Survivin-2B, a pro-apoptotic protein mainly found in primary tumors rather than high-grade tumors, could be further developed as a diagnostic marker for breast cancer (128). Caveolin-1, referred to in the above section as exosomal CD63, was reported to be increased in plasma-derived exosomes of melanoma patients, with even higher sensitivity than CD63 as a putative melanoma biomarker (81). Galectin-3-binding protein (LG3BP), a protein promoting tumor growth, was found in the serum-derived exosomes of hepatocellular carcinoma (HCC; liver cancer) patients with remarkably increased expression compared to that of the healthy control group. It was worth noting that although exosomal miRNAs in liver cancer were widely studied, there was a paucity of studies with exosomal protein biomarkers, which urged researchers to pay more attention to potential protein biomarkers for liver cancer. The diagnostic AUC of LG3BP was 0.904, which was much higher than that of a non-specific tumor marker alpha-fetoprotein (AUC = 0.802). However, another tumor marker PIGR was surprisingly found to be elevated in serum-derived exosomes with the diagnostic AUC of 0.837, higher than that of alpha-fetoprotein (93). Thus, LG3BP and PIGR may work as novel biomarkers for liver cancer together. Common cancer like lung cancer and breast cancer are both discussed in this review regarding different cancer-associated exosomal protein markers. However, rather than exosomal protein, there are much more research data in the clinical field of HCC that showed nucleic acids in exosomes including miRNA and lncRNA can act as novel biomarkers (129).

Exosomal proteins discussed in the above section almost came from the study with either plasma or serum. Other body fluids like urine or ascites, which are less viscous than plasma or serum, are much easier to deal with. Exosomes from these sources also have been revealed as potential tools for diagnosis (31). For example, a proteome profile study of urine-derived exosomes identified proteins from renal tubule epithelial cells. Polycystin-1, specifically identified in urine-derived exosomes, was associated with multiple renal diseases (107). The same group further developed an efficient protocol for urinary exosome isolation and storage (130). Different from plasma or serum-derived exosomes, urine-derived exosomes are sometimes more relevant to the urinary system, which suggests that they might possess greater potential as early liquid biopsy biomarkers for renal-related diseases. In urological cancers like prostate cancer or bladder cancer, urine-derived exosomes still display great value as diagnosis signature. One of the comprehensive proteomic studies of prostate cancer described in a review (104) suggested that TMEM256 displayed excellent accuracy for cancer diagnosis with a high AUC of 0.94 in clinical urinary samples. Nevertheless, in the discussion of another review, though another group proposed TMEM256 as a potential biomarker for prostate cancer, two other groups could not detect the presence of TMEM256 in two sets of clinical urinary samples. Moreover, the protein profiles obtained by these two groups in the urinary sample of prostate cancer were also distinct, possibly due to the different isolation and quantification methods or a different control group (131).

Moreover, there was also a study by the group of Chen et al. about a potential biomarker TACSTD2 for bladder cancer, which was significantly increased in urinary exosomes of patients.
compared to individuals with hernia (105). The great potential of TACSTD2 as a diagnostic biomarker for bladder cancer was further supported by the validation of another cohort of study (131) and by the fact that it was exclusively made by cancer cells (132). Ascite-derived exosomes are also found as a strong diagnostic tool for their expression of highly glycosylated CD133 in pancreatic cancer (106). Meanwhile, the group of Nazri et al. discovered the connection between peritoneal fluid-derived exosomes and endometriosis by systemic liquid chromatography with tandem mass spectrometry and identified five associated exosomal proteins including AXNA2 to be potential diagnostic biomarkers for endometriosis (18). The discussion about tumor-associated exosomal proteins as potential cancer biomarkers should also remind researchers of the fact that the clinical data are still limited. For example, when investigating prostate cancer, exosomal proteins including CD9, CD81, P-glycoprotein, and ACTN4 together can act as a detection panel with high specificity. CD9, CD63, or glypican-1 can be taken into consideration as generic tumor-associated markers of exosomes produced by a major group of cancers. In the future, more comprehensive research should be conducted in representative clinical cohorts to further substantiate the existing data.

**CONCLUSION AND PERSPECTIVE**

With the increasing knowledge of exosomal functions in cell–cell communication, the application of exosomal proteins as a potential tool for cancer diagnosis and liquid biopsy has become more and more attractive. Under normal circumstances, tissue biopsy or pulmonary lavage is carried out to examine the state of lung cancer, which undoubtedly causes damage to the body. Notably, in a proteomic study of non-small cell lung cancer, Li et al. demonstrated that AQP-2 (kidney tissue-related)-positive urinary exosomes expressed a high level of LRG1 protein. Similarly, LRG1 was also found highly expressed in the lung tissue of cancer patients (133). The study has presented us with a clue to the pulmonary origin of exosomes dispersed in urine and a special perspective on diagnostic utilization of urinary exosomes for lung cancer. Moreover, the discovered correlations between urine-derived exosomes and distant cancerous lung tissue encourage researchers to look deeper into the origin, transport, circulation, and uptake of exosomes.

Compared to the detection of tumors by classic antigens, the combination of exosomal protein markers offers better diagnostic results (76). Although increasing research data have suggested the importance of exosomal proteins, there are also some inconsistent and paradoxical results that we have discussed in this review among different studies, which urge a more precise investigation of exosomes. The most important reason for this result is that no standardized methodology of isolation and characterization has been established in the whole field of exosome research. Additionally, exosomes are heterogeneous, which makes the creation of standardized methods very necessary to promote the development of the clinical application of exosomal proteins. In a recent comparative study on the tetraspanin profile of exosomes, the heterogeneity of exosomes was underlined to show a strong impact on the diagnostic sensitivity of exosomal surface markers. Good consistency exists in the tetraspanin profile of exosomes from the same source regardless of isolation methods. But the results confirmed that tetraspanin profiles of exosomes from a different source are distinct (134). Additionally, other exosomal cargos can also differ among different sources. From the long-term point of view, the development of a microfluidics system is more likely to be rapidly upgraded because it represents the cutting-edge technology that can satisfy the needs of exosome investigation. Microfluidics can integrate separate isolation procedures and characterization procedures into a single platform that skips the conservation of exosomes. Even more encouraging, it can analyze multiple samples that have a small volume to detect exosomes with high throughput and high precision (135). Figure 3 shows a microfluidic system conceived by our group that delivers a general workflow or construction that can isolate and characterize tumor-derived exosomes in clinical samples.

In a recent study, Zhang et al. presented a microfluidic system in which exosomes are captured by an anti-CD63 aptamer and diagnosed by an anti-EpCAM aptamer (136). To detect those captured exosomes, a hybridization chain reaction (HCR) is applied. In this way, the signal of EpCAM aptamer on the surface of CD63⁺ exosomes is amplified in a linear form that can be detected with high sensitivity. The detection limit is confirmed as 0.5 exosomes/µl, and Zhang et al. also compared the performance of the system to that of NTA, which showed that the system could isolate cancer-derived exosomes and spare non-cancerous exosomes at the same time. Notably, a similar microfluidic aptasensor (aptamer-combined sensor) platform was constructed by Wang et al. to detect tumor-derived exosomes (137). The principle of HCR was also used, but in a different way to accurately amplify the signal of EpCAM⁺ exosomes by the formation of a multidirectional reaction. Surprisingly, the detection limit reached 285 exosomes/µl, significantly higher than that of other systems. The huge difference that existed between the two systems suggested that the mechanism applied for the amplification and detection of signals in an aptasensor system had a great impact on the sensitivity. However, a remaining issue of these two studies is that the exosomes they used for testing are enriched either by ultracentrifugation of supernatant of cell culture or by isolation of human serum with commercial isolation kit. Therefore, the detection sensitivity and limit of these two systems for exosomal EpCAM diagnosis of more complicated clinical samples without exosome enrichment remain unknown. Moreover, in these two studies, the use of a single biomarker CD63 for exosome capture resulted in the omission of exosomes deprived of surface CD63. Similarly, use of single biomarker EpCAM resulted in the omission of tumorous exosomes lack of EpCAM.

While these issues are taken into consideration in our proposed model (Figure 3), the combination of multiple...
Exosomal surface markers in this model can promote the probability to capture almost all exosomes in samples; however, the actual performance of the device still relies on the specificity of current exosomal markers and the identification of novel exosomal markers. Moreover, the sensitivity for detecting or capturing tumor-derived exosomes by the model also relies on the binding affinity of tumor-associated aptamers to exosomes, as well as the technique applied. The exclusion of non-cancerous exosomes would be favored by the technical improvement of detection strategy and the discovery of some novel tumor markers with high specificity, which would result in the enrichment of cancerous exosomes. For clinical use of exosomes, the methods should be handy, highly efficient, and supersensitive. The methods should also be compatible with different clinical samples. When dealing with blood, coagulation will cause the release of platelet-derived exosomes in the serum; thus it is better to choose plasma for exosome isolation (138). However, coagulation sometimes happens with cancer progression; thus, it is extremely necessary to distinguish tumor-derived exosomes from immune cell-derived exosomes in the blood sample, which further emphasizes the need for the discovery of tumor-specific exosomal markers. Additionally, the development of cancer-stage-specific exosomal markers is also very attractive to the current precision medicine theory.

It is worth mentioning that the standardization of exosome isolation methods will favor future clinical utilization of exosomes for immunotherapy at the same time. Safety is the most important issue to be concerned about when talking about therapy, which holds back many cell-therapy strategies. On the contrary, the high purity of exosome products will be a strong candidate for therapeutic treatment. For example, mesenchymal stem cell (MSC)-derived exosomes have already been proved to mediate immune response in multiple murine models with acute graft-versus-host disease (aGVHD) due to their anti-inflammatory or immunomodulatory effects. MSC-derived exosomes can promote the expansion of regulatory T cells, which suppress the inflammatory response and can also induce the production of anti-inflammatory cytokines like IL-10 while inhibiting the production of inflammatory cytokines like TNF-α (139, 140). In a typical clinical treatment against aGVHD, the response of patients to MSC-derived exosomes administration was found to be positive, and the clinical GVHD symptom was significantly improved, suggesting the great potential of MSC-derived exosomes for clinical therapies (141). Beyond that, the function of MSC-derived exosomes has also been recently introduced into the treatment of COVID-19 for the first time. Patients infected with COVID-19 received 5 days of MSC-derived exosome infusion. At the endpoint, data showed that the percentage of CD3+, CD4+, and CD8+ T cells increased in patients, implying the exciting outcome of immunomodulatory effects of MSC-derived exosomes (142).

In summary, it is believed that with the advancement of isolation technique and characterization strategy, the clinical application of exosomal proteins would finally act as a powerful diagnostic target in liquid biopsy as well as effective immunotherapy.

**AUTHOR CONTRIBUTIONS**

CH and WJ drafted the manuscript. ML, SF, and YL helped to revise the manuscript. JP and QW were responsible for leading

---

**FIGURE 3** | A design of microfluidics system for clinical exosome isolation and characterization with high efficiency and high sensitivity. The first module of the system is a pore matrix (pore size ~200 nm). When microliters of plasma/serum is injected through the injection port 1, pressure will be added to the module, which makes particles inside the sample move toward the pore matrix. Nanoparticles including exosomes will move through pore matrix, while large particles will be left in the chamber. Then, phosphate-buffered saline (PBS) solution is injected into the chamber to create reflux to wash the pore matrix to ensure all exosomes move across the matrix and reach the one-way valve. In the second module, exosomes were captured in a characterization chamber. Enough quantities of DNA aptamers that specifically recognize exosome surface proteins like CD63, CD81, and CD9 are immobilized on the plane. Exosomes were captured while flowing across the plane, and buffer was injected through port 2. Impurities were discharged through the waste port. After that, tagged DNA aptamers that specifically recognize tumor-specific antigens were injected through port 3, and tumor-derived exosomes were bound by these aptamers. Finally, the chemiluminescence reagent was injected through port 4 and reacted with the tagged aptamers. The chemical signal was captured and exported eventually.
this work and revising the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING
This study was supported by the Open Research Fund of Songshan Lake Materials Laboratory (2021SLABFN10), the Natural Science Foundation of Guangdong Province (2022A1515011223), Project of Educational Commission of Guangdong Province of China (2021KTSCX038), and Funds for PhD researchers of Guangdong Medical University in 2021 (4SG21236G and 4SG22067G).

REFERENCES

1. Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, et al. Urine as a Source of Liquid Biopsy for Cancer. Cancers (Basel) (2021) 13 (11):2652. doi:10.3390/cancers13112652
2. Watanabe K, Nakamura Y, Low SK. Clinical Implementation and Current Advancement of Blood Liquid Biopsy in Cancer. J Hum Genet (2021) 66 (9):909–26. doi:10.1038/s41008-021-00939-5
3. Wu L, Wang Y, Zhu L, Liu Y, Wang T, Liu D, et al. Aptamer-Based Liquid Biopsy. ACS Appl Bio Materials (2020) 3(5):2743–64. doi:10.1021/acs.abm.9b01194
4. Gormaly E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malavelle C, et al. Amount of DNA in Plasma and Cancer Risk: A Prospective Study. Int J Cancer (2004) 111(5):746–9. doi:10.1002/ijc.20327
5. Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A, et al. Circulating Tumor Cell Isolation, Culture, and Downstream Molecular Analysis. Biotechnol Adv (2018) 36(4):1063–78. doi:10.1016/j.biotechadv.2018.03.007
6. Wu CP, Wu P, Zhao HF, Liu WL, Li WP. Clinical Applications of and Challenges in Single-Cell Analysis of Circulating Tumor Cells. DNA Cell Biol (2018) 37(2):78–89. doi:10.1089/dna.2017.3981
7. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and Quantification of Mutations in the Plasma of Patients With Colorectal Tumors. Proc Natl Acad Sci USA (2005) 102(45):16368–73. doi:10.1073/pnas.0507990102
8. Schwarzenbach H, Hoon DS, Pantel K. Circulating Tumor Cells in Cancer Development, Micro- and Nano-Based Devices. Exosomes and Microvesicles for Cancer Monitoring and Diagnostics. Cancer (Basel) (2021) 13 19(2):2147. doi:10.3390/cancers13092147
9. Vaidyanathan R, Soon RH, Zhang P, Jiang K, Lim CT. Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond. Lab Chip (2018) 19(1):11–34. doi:10.1039/c7lc00854a
10. Ko J, Carpenter E, Issadore D. Detection and Isolation of Circulating Exosomes and Microvesicles for Cancer Monitoring and Diagnostics Using Micro-/Nano-Based Devices. Analyst (2016) 141(2):450–60. doi:10.1039/c5an01610j
11. Valencia K, Montuenga LM. Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. Cancers (Basel) (2011) 11(6):426–37. doi:10.3390/cancers11060396
12. Lombrardi CP, Bosolla M, Princi P, Boscherini M, La Torre G, Raffaelli M, et al. Circulating Thryoglobulin mRNA Does Not Predict Early and Midterm Recurrences in Patients Undergoing Thyroidectomy for Cancer. Am J Surg (2008) 196(3):326–32. doi:10.1016/j.amjsurg.2007.09.047
13. Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y, et al. Application of Exosomes as Liquid Biopsy in Clinical Diagnosis. Signal Transduct Target Ther (2020) 5(1):144. doi:10.1038/s41392-020-00258-9
14. Li W, Li C, Zhou T, Liu X, Liu X, Li X, et al. Role of Exosomal Proteins in Cancer Diagnosis. Mol Cancer (2017) 16(1):145. doi:10.1186/s12943-017-0706-8
15. Fitts CA, Ji N, Li Y, Tan C. Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery. Adv Healthc Mater (2019) 8(6):e1801268. doi:10.1002/adhm.201801268
16. Liu Y, Shi K, Chen Y, Wu X, Chen Z, Cao K, et al. Exosomes and Their Role in Cancer Progression. Front Oncol (2021) 11:639159. doi:10.3389/fonc.2021.639159

ACKNOWLEDGMENTS
We apologize to those authors whose deserving research was not cited in this manuscript.
42. Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, et al.
41. Yoshizaki T, Kondo S, Wakisaka N, Murono S, Endo K, Sugimoto H, et al.
34. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al.
30. Witwer KW, Buzas EI, Bemis LT, Bora A, Lasser C, Lotvall J, et al.
22. doi: 10.1074/jbc.M109.041152
19. Y. Kawasaki T, Suyoshi T, Kobayama K, Ishii KJ, Zou J, et al. DNA-Containing Exosomes Derived From Cancer Cells Treated With Topotecan Activate a STING-Dependent Pathway and Reinvigorate Antitumor Immunity. J Immunol (2017) 198(4):1649–59. doi: 10.4049/jimmunol.1601694
7. Karimi N, Cvjetkovic A, Jang SC, Crescitelli R, Hosseinpour Feizi MA, et al. Liposome-Mediated Detection of SARS-CoV-2 RNA-Positive Exosomes in Plasma. Nat Nanotechnol (2021) 16(9):1039–44. doi: 10.1038/s41565-021-00939-9
6. Sheller-Miller S, Trivedi J, Yelloy SM, Menon R. Exosomes Cause Preterm Birth in Mice: Evidence for Paracrine Signaling in Pregnancy. Sci Rep (2019) 9(1):608. doi: 10.1038/s41598-018-37002-x
5. Benaroch P, et al. Exosomes Bearing HLA-DR1 Molecules Need Dendritic Cell Antigen Presentation Efficiency of the Molecules. J Immunol (2015) 195(1):607. doi: 10.1007/s00018-015-2773-4
4. Ting X, Zhu T, Yang C, Hu Y, Wang T, Wang Y, et al. Exosomes Uptake Through Clathrin-Mediated Endocytosis and Macropinocytosis and Mediating miR-21 Delivery. J Biol Chem (2014) 289(32):22258–67. doi: 10.1074/jbc.M114.588046
3. Tufan T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, et al. Exosome Isolated by Different Methods. Sci Rep (2020) 10(1):14069. doi: 10.1038/s41598-020-70584-z
2. Taylor DD, Shah S. Methods of Isolating Exacellular Vesicles Impact Down-Stream Analyses of Their Cargoes. Methods (2015) 87:3–10. doi: 10.1016/j.ymeth.2015.02.019
1. Nakai W, Yoshida T, Diez D, Miyatake Y, Nishibu T, Imamura N, et al. A Novel Affinity-Based Method for the Isolation of Highly Purified Exosomes. Sci Rep (2016) 6359355. doi: 10.1038/srep35935
0. Witwer KW, Buzas EI, Bemis LT, Bora A, Lasser C, Lotvall J, et al. Exosomal Proteins for Liquid Biopsy. J Extracell Vesicles (2013) 2(1):20360. doi: 10.3402/jev.v2i0.20360
45. Jung HH, Kim JY, Lim YJ, Im YH. Cytokine Profiling in Serum-Derived Exosomes Isolated by Different Methods. Cell Rep (2020) 10(1):14069. doi: 10.1038/s41598-020-70584-z
44. Daniels KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-Cells and Their Surrounding. Essential Exosome Components for the Crosstalk Between Cancer Initiating Cells to Effectively Stimulate Specific T Cells. Int Immunol (2002) 14(7):713–22. doi: 10.1093/intimm/dxf048
43. Qu Jl, Qu Xj, Zhao MF, Teng YE, Zhang Y, Hou KZ, et al. Gastric Cancer Exosomes Promote Tumour Cell Proliferation Through PI3K/Akt and MAPK/ERK Activation. Dig Liver Dis (2009) 41(12):875–80. doi: 10.1016/j.dld.2009.08.044
42. Yang L, Wu XH, Wang D, Luo CL, Chen LX. Bladder Cancer Cell-Derived Exosomes Inhibit Tumor Cell Apoptosis and Induce Cell Proliferation In Vitro. Mol Med Rep (2013) 8(4):1277–8. doi: 10.3892/mmr.2013.1634
41. Aga M, Bentz GL, Raffa S, Torrisi MR, Kondo S, Wakisaka N, et al. Exosomal HIF1alpha Supports Invasive Potential of Nasopharyngeal Carcinoma-Associated LMP1-Positive Exosomes. Oncogene (2014) 33(37):4613–22. doi: 10.1038/onc.2014.66
40. Yoshizaki T, Kondo S, Wakisaka N, Murono S, Endo K, Sugimoto H, et al. Pathogenic Role of Epstein-Barr Virus Latent Membrane Protein-1 in the Development of Nasopharyngeal Carcinoma. Cancer Lett (2015) 337(1):1–7. doi: 10.1016/j.canlet.2013.05.018
39. Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marinri A, Pintus G, et al. Carboxylic Anhydrase IX From Cancer-Associated Fibroblasts Drives Epithelial-Mesenchymal Transition in Prostate Carcinoma Cells. Cell Cycle (2013) 12(11):1791–801. doi: 10.4161/cc.24902
38. Yue S, Mu W, Erb U, Zoller M. The Tetrascarnins CD151 and Tspan8 Are Essential Exosome Components for the Crosstalk Between Cancer Initiating Cells and Their Surrounding. Oncotarget (2015) 6(4):2356–84. doi: 10.18632/oncotarget.2958
37. Isolberi G, Nomak MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, et al. Hypoxia-Tumor-Derived Microvesicles Negatively Regulate NK Cell Function by a Mechanism Involving TGF-Beta and Mi23A Transfer. Oncotarget (2015) 6(4):e026596. doi: 10.18632/oncotarget.2015.02698
36. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: Mediators of Cancer-Associated Immun suppressive Microenvironments. Semin Immunopathol (2011) 33(3):441–54. doi: 10.1007/s00018-010-0234-8
35. Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial Ovarian Cancer- Secreted Exosomal miR-222-3p Induces Polarization of Tumor-Associated Macrophages. Oncotarget (2016) 7(28):43076–87. doi: 10.18632/oncotarget.9246
34. Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen J, et al. Pancreatic Cancer-Derived Exosomes Transfer miRNAs to Dendritic Cells and Inhibit RFXAP Expression via miR-212-3p. Oncotarget (2015) 6(30):29877–88. doi: 10.18632/oncotarget.4924
33. Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-Associated Fibroblast Exosomes Regulate Survival and Proliferation of Pancreatic Cancer Cells. Oncogene (2017) 36(13):1770–8. doi: 10.1038/onc.2016.353
32. Momen-Heravi F, Balaj L, Alain S, Trachtenberg AJ, Hochberg FH, Skog J, et al. Impact of Biofluid Viscosity on Size and Sedimentation Efficiency of the Isolated Microvesicles. Front Physiol (2012) 3:162. doi: 10.3389/ fphys.2012.00162
31. Wittwer KW, Buzas EL, Benis LT, Bora A, Lasser C, Lotvall J, et al. Standardization of Sample Collection, Isolation and Analysis Methods in Extracellular Vesicle Research. J Extracell Vesicles (2013) 2(1):20360. doi: 10.3402/jev.v2i0.20360
69. Li C, Zhou Y, Liu J, Su X, Qin H, Huang S, et al. Potential Markers From Serum-Purified Exosomes for Detecting Oral Squamous Cell Carcinoma Metastasis in Cancer Epidemiology Biomarkers Prev (2019) 28(10):6688–81. doi: 10.1158/1055-9965.EPI-18-1122

70. Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming Limitations of Microparticle Measurement by Flow Cytometry. Semin Thromb Hemost (2010) 36(8):807–18. doi: 10.1055/s-0030-1267034

71. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primald-Bengston B, et al. Proteomic Comparison Defines Novel Markers to Characterize Heterogeneous Populations of Extracellular Vesicle Subtypes. Proc Natl Acad Sci USA (2016) 113(8):E968–77. doi: 10.1073/pnas.1521203113

72. Conterras-Naranjo JC, Wu HJ, Ugas VM. Microfluidics for Exosome Isolation and Analysis: Enabling Liquid Biopsy for Personalized Medicine. Lab Chip (2017) 17(23):3558–77. doi: 10.1039/c7lc00592j

73. Ueda K, Ishikawa N, Tatsuguchi A, Saitoh N, Fujii R, Nakagawa H. Antibody-Coupled Monolithic Silica Microtrops for Highthroughput Molecular Profiling of Circulating Exosomes. Sci Rep (2014) 4, 6232. doi: 10.1038/srep06232

74. Sandfeld-Paulsen B, Jakobsen KR, Baek R, Folkersen BH, Rasmussen TR, Meldgaard P, et al. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. J Thorac Oncol (2016) 11(10):1701–10. doi: 10.1016/j.jtho.2016.05.034

75. Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, et al. Exosomal Protein CD82 as a Diagnostic Biomarker for Precision Medicine for Breast Cancer. Mol Carcinog (2020) 59(8):7674–85. doi: 10.1002/mc.29266

76. Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, et al. Serum-Purified Exosomes as Potential Markers for Detecting Oral Squamous Cell Carcinoma. In Vivo (2014) 5, 3591. doi: 10.1081/nccmsn5491

77. Madhavan B, Yue S, Galli U, Rana S, Gross W, Muller M, et al. Combined Evaluation of a Panel of Protein and mRNA Serum-Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity. Int J Cancer (2015) 136(11):2616–27. doi: 10.1002/ijc.29324

78. Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, et al. Prostate Cancer Studies the alpha1beta3 Integrin In Vivo Through Exosomes. Matrix Biol (2019) 85(6):674–85. doi: 10.1016/j.matbio.2018.08.004

79. Soekmadji C, Riches JD, Russell PJ, Rueckle JE, McPherson S, Wang C, et al. Modulation of Paracrine Signaling by CD9 Positive Small Extracellular Vesicles Mediates Cellular Growth of Androgen Deprived Prostate Cancer. Oncotarget (2017) 8(32):52237–55. doi: 10.18632/oncotarget.11111

80. Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, et al. Serum Exosomal P-Glycoprotein Is a Potential Marker to Diagnose Docetaxel Resistance and Select a Taxoid for Patients With Prostate Cancer. Urol Oncol (2015) 33(9):e35–20. doi: 10.1016/j.urolonc.2015.04.019

81. Logozzi M, De Milito A, Laguna L, Bologn M, Calabro L, Spada M, et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS One (2009) 4(4):e5219. doi: 10.1371/journal.pone.0005219

82. Rodriguez Zorrilla S, Perez-Sayans M, Fais S, Logozzi M, Gallas Torreira B, Garcia Garcia A. A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients. Cancers (Basel) (2019) 11(3):429. doi: 10.3390/cancers11030429

83. Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Logozzi M, et al. Monitoring of Circulating Exosomes. Lab Chip (2016) 16(3):489. doi: 10.1039/c5lc00586f

84. Xiao D, Dong Z, Zhen L, Xia G, Huang X, Wang T, et al. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer. Mol Cancer Res (2020) 18(2):300–10. doi: 10.1158/1541-7768.MCR-19-0588

85. Buscall E, Chauvet A, Quincy P, Degrandi O, Buscall C, Lamrissi I, et al. CD63-GPC1-Positive Exosomes Coupled With CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Transl Oncol (2019) 12(1):1395–403. doi: 10.1016/j.tranon.2019.07.009

86. Zhao Z, Yang Y, Zeng Y, He M. A Microfluidic Exosome Chip for Multiplexed Exosome Detection Towards Blood-Based Ovarian Cancer Diagnosis. Lab Chip (2016) 16(3):489–96. doi: 10.1039/c5lc01117e

87. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 Contributes to Immunosuppression and Is Associated With Anti-PD-1 Response. Nature (2018) 560(7718):382–6. doi: 10.1038/s41586-018-0392-8

88. Theodaraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients. Clin Cancer Res (2018) 24(4):896–905. doi: 10.1158/1078-0432.CCR-17-2664

89. Enroth LA, Böttger F, Bijsendorp IV, Jimenez CR. Urinary Exosomal Proteins as (Pan-)Cancer Biomarkers: Insights From the Proteome. FERS Lett (2019) 59(13):1508–97. doi: 10.1016/j.fersl.2018.07.009

90. Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH, et al. Comparative and Targeted Proteomic Analyses of Urinary Microparticles From Bladder Cancer Patients. Cancers (Basel) (2015) 7:250. doi: 10.3390/cancers7030250

91. Chanteloup G, Cordonnier M, I sambert N, Bertaut A, Hervieu A, Logozzi M, et al. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. Oncotarget (2018) 9(1):24873–4. doi: 10.18632/oncotarget.25016

92. Lux A, Kahler C, Graumann R, Pilsarzky C. C-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. Int J Mol Sci (2019) 20(13):3305. doi: 10.3390/ijms20133305

93. Melo SA, Luecke LB, Kahler C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 Identifies Cancer Exosomes and Detects Early Pancreatic Cancer. Nature (2015) 523(7559):177–82. doi: 10.1038/nature14581

94. Frampton AE, Prado MM, Lopez-Jimenez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, et al. Glypican-1 Is Enriched in Circulating Exosomes in Pancreatic Cancer and Correlates With Tumor Burden. Oncotarget (2018) 9(21):19006–13. doi: 10.18632/oncotarget.24873
117. Oh KB, Stanton MJ, West WW, Todd GL, Wagner KU. Tsg101 is
109. He M, Crow J, Roth M, Zeng Y, Godwin AK. Integrated
106. Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, et al.
120. Gheytanchi E, Saeednejad Zanjani L, Ghods R, Abolhasani M, Shahin M,
119. Albakova Z, Siam MKS, Sacitharan PK, Ziganshin RH, Ryazantsev DY,
118. Yang J, Zhang Y, Gao X, Yuan Y, Zhao J, Zhou S, et al. Plasma-Derived
113. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A
121. Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM.
124. Li N, Gao W, Zhang Y-F, Ho M. Glypicans as Cancer Therapeutic Targets.
127. Soltesz B, Lukacs J, Szilagyi E, Marton E, Szilagyi Bonizs M, Penyige A, et al. Tetraspanins Are Unevenly Distributed Across Single Extracellular Vesicles and Bias Sensitivity to Multiplexed Cancer Biomarkers. *J Nanobiotechnol* (2017) 15(8):e0236439. doi: 10.1371/journal.pone.0236439
128. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, et al. Early Diagnostic Value of Survivin and Its Alternative Splice Variants in Breast Cancer. *BMC Cancer* (2014) 14:176. doi: 10.1186/1471-2407-14-176
129. Wang H, Lu Z, Zhao X. Tumorigenesis, Diagnosis, and Therapeutic Potential of Exosomes in Liver Cancer. *J Hematol Oncol* (2019) 12(1):133. doi: 10.1186/s13045-019-0806-6
130. Zhou H, Yuan PS, Pisitkun T, Gonzales PA, Yasuda H, Dear JW, et al. Collection, Storage, Preservation, and Normalization of Human Urinary Exosomes for Biomarker Discovery. *Kidney Int* (2006) 69(8):1471–8. doi: 10.1038/sj.ki.5000273
131. Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM. Targeted Overexpression in Transgenic Mice Reveals Weak Oncogenic JNK Signaling. *Cell Death Dis* j.1365-2567.2005.02316.x
132. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for Graft-Versus-Host Disease. *Stem Cells* (2020) 38(5):698–711. doi: 10.1002/stem.3160
133. Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic Identification of Exosomal LRG1: A Potential Urinary Biomarker for Detecting NSCLC. *Electrophoresis* (2011) 32(15):1976–83. doi: 10.1002/elps.201000598
134. Mizenko RR, Brostoff T, Rojalin T, Koster HJ, Swindell HS, Leiservowitz GS, et al. Tetraspanins Are Unevenly Distributed Across Single Extracellular Vesicles and Bias Sensitivity to Multiplexed Cancer Biomarkers. *J Nanobiotechnol* (2019) 17(1):250. doi: 10.1186/s12951-020-00987-1
135. Lin S, Yu Z, Chen D, Wang Z, Miao J, Li Q, et al. Progress in Microfluidic-Based Exosome Separation and Detection Technologies for Diagnostic Applications. *Small* (2020) 16(9):e1903916. doi: 10.1002/smll.201903916
136. Zhang W, Tian Z, Yang S, Rich J, Zhao S, Klineborg M, et al. Electrochemical Microbes as Carriers for Exosome Detection Based on Hybridization Chain Reaction Amplification. *Microsystems Nanoeng* (2021) 7(1):63. doi: 10.1038/s41378-021-00293-8
137. Wang L, Zeng L, Wang Y, Chen T, Chen W, Chen G, et al. Electrochemical Aptasensor Based on Multidirectional Hybridization Chain Reaction for Detection of Tumorous Exosomes. *Sensors Actuators B: Chem* (2021) 332:129471. doi: 10.1016/j.snb.2021.129471
138. Palvainen M, Saraswat M, Varga Z, Kitka D, Neuvonen M, Puhka M, et al. Extracellular Vesicles From Human Plasma and Serum Are Carriers of Extravascular-Cargo Implications for Biomarker Discovery. *PloS One* (2020) 15(6):e0236439. doi: 10.1371/journal.pone.0236439
139. Dal Collo G, Adamo A, Gatti A, Tamellini E, Bazzoni R, Takam Kamga P, et al. Functional Dosing of Mesenchymal Stromal Cell-Derived Extracellular Vesicles for the Prevention of Acute Graft-Versus-Host-Disease. *Stem Cells* (2020) 38(5):698–711. doi: 10.1002/stem.3160
140. Lai P, Chen X, Guo L, Wang Y, Liu X, Liu Y, et al. A Potent Immunomodulatory Role of Exosomes Derived From Mesenchymal Stromal Cells in Preventing cGVHD. *J Hematol Oncol* (2018) 11(1):135. doi: 10.1186/s13045-018-0860-7
141. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-Derived Exosomes: A Novel Tool to Treat Therapy-Refractory Graft-Versus-Host Disease. *Leukemia* (2014) 28(4):970–3. doi: 10.1038/leu.2014.41
142. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for
Severe COVID-19. *Stem Cells Dev* (2020) 29(12):747–54. doi: 10.1089/scd.2020.0080

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hu, Jiang, Lv, Fan, Lu, Wu and Pi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.